A.R.T. Advisors LLC bought a new position in shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) during the 1st quarter, HoldingsChannel.com reports. The fund bought 58,576 shares of the company’s stock, valued at approximately $1,173,000.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Millennium Management LLC increased its holdings in shares of Deciphera Pharmaceuticals by 5.9% during the fourth quarter. Millennium Management LLC now owns 728,583 shares of the company’s stock worth $16,517,000 after purchasing an additional 40,352 shares during the period. BlackRock Inc. increased its holdings in shares of Deciphera Pharmaceuticals by 37.5% during the first quarter. BlackRock Inc. now owns 499,879 shares of the company’s stock worth $10,018,000 after purchasing an additional 136,396 shares during the period. Opaleye Management Inc. bought a new position in shares of Deciphera Pharmaceuticals during the first quarter worth approximately $7,314,000. Lord Abbett & CO. LLC increased its holdings in shares of Deciphera Pharmaceuticals by 29.7% during the first quarter. Lord Abbett & CO. LLC now owns 350,331 shares of the company’s stock worth $7,020,000 after purchasing an additional 80,207 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Deciphera Pharmaceuticals by 64.3% during the first quarter. JPMorgan Chase & Co. now owns 287,762 shares of the company’s stock worth $5,767,000 after purchasing an additional 112,581 shares during the period. 47.68% of the stock is currently owned by institutional investors.
Several research analysts have recently commented on DCPH shares. JPMorgan Chase & Co. raised their target price on shares of Deciphera Pharmaceuticals from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Monday, June 4th. BidaskClub cut shares of Deciphera Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 15th. Zacks Investment Research cut shares of Deciphera Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, April 4th. B. Riley decreased their price objective on shares of Deciphera Pharmaceuticals from $52.00 to $43.00 and set a “buy” rating on the stock in a research note on Wednesday, May 9th. Finally, Piper Jaffray Companies lifted their price objective on shares of Deciphera Pharmaceuticals to $50.00 and gave the company an “overweight” rating in a research note on Tuesday, June 12th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Deciphera Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $47.57.
Shares of Deciphera Pharmaceuticals opened at $39.55 on Friday, Marketbeat reports. The company has a market capitalization of $1.69 billion and a P/E ratio of -13.23. The company has a current ratio of 11.12, a quick ratio of 11.12 and a debt-to-equity ratio of 0.01. Deciphera Pharmaceuticals Inc has a 1 year low of $15.15 and a 1 year high of $45.61.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings data on Tuesday, May 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). equities analysts predict that Deciphera Pharmaceuticals Inc will post -2.72 EPS for the current fiscal year.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Want to see what other hedge funds are holding DCPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Deciphera Pharmaceuticals Inc (NASDAQ:DCPH).
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.